Loading
Discovered the MYD88 mutation that defines Waldenström macroglobulinaemia and led the trial that made ibrutinib its first approved drug.
Steven Treon led the whole-genome sequencing that found the MYD88 L265P mutation in more than 90% of Waldenström macroglobulinaemia, a diagnostic marker and therapeutic target, and then the pivotal trial of ibrutinib that produced the disease's first FDA approval. He identified CXCR4 mutations as a resistance mechanism and directs the world's largest Waldenström research centre at Dana-Farber.
| Title | Journal | Year |
|---|---|---|
| MYD88 L265P somatic mutation in Waldenström's macroglobulinemia | NEJM | 2012 |
| Ibrutinib in previously treated Waldenström's macroglobulinemia | NEJM | 2015 |
Shares Dana-Farber Brigham Cancer Center, Whole-exome & whole-genome sequencing and the tag genomics.
Shares Waldenström macroglobulinaemia, Small-molecule kinase inhibitors.
Shares Waldenström macroglobulinaemia, Small-molecule kinase inhibitors.
Shares Whole-exome & whole-genome sequencing and the tag genomics.
Shares Dana-Farber Brigham Cancer Center and the tag lymphoma.
Shares Whole-exome & whole-genome sequencing and the tag genomics.
Shares Whole-exome & whole-genome sequencing and the tag genomics.
Shares Whole-exome & whole-genome sequencing and the tag genomics.